Mesenchymal stem cells in tumor microenvironment: drivers of bladder cancer progression through mitochondrial dynamics and energy production.
Yang E, Jing S, Wang F, Wang H, Fu S, Yang L, Tian J, Golijanin DJ, El-Deiry WS, Cheng L, Wang Z.
Cell Death Dis. 2024 Sep 20;15(9):688. doi: 10.1038/s41419-024-07068-9.
Single-cell RNA sequencing reveals the epithelial cell heterogeneity and invasive subpopulation in human bladder cancer.
Lai H, Cheng X, Liu Q, Luo W, Liu M, Zhang M, Miao J, Ji Z, Lin GN, Song W, Zhang L, Bo J, Yang G, Wang J, Gao WQ.
Int J Cancer. 2021 Dec 15;149(12):2099-2115. doi: 10.1002/ijc.33794. Epub 2021 Sep 16.
FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.
Noeraparast M, Krajina K, Pichler R, Niedersüß-Beke D, Shariat SF, Grünwald V, Ahyai S, Pichler M.
Cancer Commun (Lond). 2024 Oct;44(10):1189-1208. doi: 10.1002/cac2.12602. Epub 2024 Aug 19.
[Mesenchymal tumors of the urinary bladder].
Agaimy A, Hartmann A.
Pathologe. 2016 Feb;37(1):61-70. doi: 10.1007/s00292-015-0122-z.
Mesenchymal tumours of the bladder and prostate: an update.
Tavora F, Kryvenko ON, Epstein JI.
Pathology. 2013 Feb;45(2):104-15. doi: 10.1097/PAT.0b013e32835c768b.
Origins of Bladder Cancer.
Czerniak B, Dinney C, McConkey D.
Annu Rev Pathol. 2016 May 23;11:149-74. doi: 10.1146/annurev-pathol-012513-104703. Epub 2016 Feb 22.
TGF-beta1 dominates stromal fibroblast-mediated EMT via the FAP/VCAN axis in bladder cancer cells.
Ping Q, Wang C, Cheng X, Zhong Y, Yan R, Yang M, Shi Y, Li X, Li X, Huang W, Wang L, Bi X, Hu L, Yang Y, Wang Y, Gong R, Tan J, Li R, Li H, Li J, Wang W, Li R.
J Transl Med. 2023 Jul 17;21(1):475. doi: 10.1186/s12967-023-04303-3.
Primary Sarcomatoid Tumor of the Bladder: A Different Entity but the Same Approach?
Molina-Cerrillo J, Martínez-Sáez O, Alonso-Gordoa T, Tirado-Zambrano P, Delgado-Vargas B, Earl J, Grande E.
Clin Genitourin Cancer. 2015 Dec;13(6):493-8. doi: 10.1016/j.clgc.2015.05.001. Epub 2015 May 13.
Malignant solitary fibrous tumor of urinary bladder: A rare clinical entity.
Kratiras Z, Spapis V, Koniaris E, Kozyrakis D, Skriapas K.
Arch Ital Urol Androl. 2019 Jul 2;91(2). doi: 10.4081/aiua.2019.2.135.
BAIAP2 as a driver of tumor progression in urothelial bladder cancer.
Huang L, Yan D, Ruan H, Lin Q, Qin H.
BMC Cancer. 2025 Jul 1;25(1):1057. doi: 10.1186/s12885-025-14470-9.
